BioGend Therapeutics Dirección

Dirección controles de criterios 0/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	sin datos
Promedio de permanencia en la Junta Directiva	sin datos

Actualizaciones recientes de la dirección

Recent updates

Here's Why We're Not At All Concerned With BioGend Therapeutics' (GTSM:6733) Cash Burn Situation

Mar 24

We Think BioGend Therapeutics (GTSM:6733) Can Afford To Drive Business Growth

Dec 10

CEO

BioGend Therapeutics no tiene CEO, o no tenemos datos al respecto.

BioGend Therapeutics Dirección

Dirección controles de criterios 0/4

Información clave

Actualizaciones recientes de la dirección

BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024

BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021

Recent updates

Third quarter 2024 earnings released: NT$0.25 loss per share (vs NT$0.35 loss in 3Q 2023)

BioGend Therapeutics Co., Ltd. to Report Q3, 2024 Results on Nov 08, 2024

Second quarter 2024 earnings released: NT$0.28 loss per share (vs NT$0.26 loss in 2Q 2023)

BioGend Therapeutics Co., Ltd. to Report Q2, 2024 Results on Aug 08, 2024

BioGend Therapeutics Co., Ltd. Announces Hsinchu Factory Pass the Domestic Medical Device Quality Management System (Qms) Manufacturing License

First quarter 2024 earnings released

Full year 2023 earnings released: NT$1.30 loss per share (vs NT$1.79 loss in FY 2022)

BioGend Therapeutics Co., Ltd., Annual General Meeting, May 28, 2024

New minor risk - Share price stability

Third quarter 2023 earnings released: NT$0.36 loss per share (vs NT$0.51 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: NT$0.26 loss per share (vs NT$0.33 loss in 2Q 2022)

Full year 2022 earnings released: NT$1.79 loss per share (vs NT$1.37 loss in FY 2021)

Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021)

Third quarter 2022 earnings released: NT$0.50 loss per share (vs NT$0.39 loss in 3Q 2021)

Second quarter 2022 earnings released: NT$0.33 loss per share (vs NT$0.38 loss in 2Q 2021)

First quarter 2022 earnings released: NT$0.43 loss per share (vs NT$0.47 loss in 1Q 2021)

Third quarter 2021 earnings released: NT$0.39 loss per share (vs NT$0.48 loss in 3Q 2020)

First quarter 2021 earnings released: NT$0.47 loss per share (vs NT$0.42 loss in 1Q 2020)

Here's Why We're Not At All Concerned With BioGend Therapeutics' (GTSM:6733) Cash Burn Situation

BioGend Therapeutics Co., Ltd., Annual General Meeting, Jun 08, 2021

Full year 2020 earnings released: NT$1.67 loss per share (vs NT$2.01 loss in FY 2019)

New 90-day low: NT$27.75

New 90-day low: NT$31.20

We Think BioGend Therapeutics (GTSM:6733) Can Afford To Drive Business Growth

New 90-day low: NT$38.75

Third quarter 2020 earnings released: NT$0.48 loss per share

CEO